A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Moscow Clinical Scientific Center285 enrolled

Overview

This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies

Study Type

OBSERVATIONAL

Enrollment

285

Conditions

Solid Tumor High-Risk Cancer Breast Cancer Gastrointestinal Cancer Gynecological Malignancies Myelosuppression

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed informed consent form; 2. Histologically verified diagnosis; 3. Age between 18 and 80 years; If the patient had previously received chemotherapy for these indications, then it should be completed at least 30 days before the first administration of the study drug; 4. ECOG performance 0-2; 5. Haematology: * ANC ≥ 1,5 х 10(9) /L; * Platelets ≥ 100 х 10(9) /L; * Hemoglobin ≥ 90 g/L; 6. Biochemistry: * Creatinine ≤ 1,5 ULN; * Total bilirubin ≤ 1,5 ULN; * AST/ALT ≤ 2,5 ULN; * Alkaline phosphatase ≤ 5 ULN; 8\. Life expectancy of at least 6 months from the date of the first drug administration in the study; 9. Ability of the patient to comply with the Protocol requirements. Exclusion Criteria: 1. Documented hypersensitivity to empegfilgrastim, filgrastim, pegfilgrastim, and / or their constituent excipients: pegylated drugs, protein recombinant drugs; 2. Systemic use of antibiotics less than 72 hours before the first drug administration in the study; 3. Concurrent or less than 30 days before the start of the study, radiation therapy (with the exception of point radiation therapy for bone metastases); study; 4. Concurrent participation in clinical trials, participation in clinical trials within the previous 30 days, previous participation in this study; 5. Surgical treatment less than 21 days (3 weeks) prior to study enrollment; taking any experimental medications less than 30 days before enrollment in this study; 6. History of bone marrow or hematopoietic stem cell transplantation; 7. Presence of acute or active chronic infections; 8. Other diseases (with the exception of the main one) that could affect the assessment of the severity of the symptoms of the underlying disease: that may mask, enhance, change the symptoms of the underlying disease or cause clinical manifestations and changes in the data of laboratory and instrumental research methods; 9. Inability to administer the drug by intravenous infusion or subcutaneous injection.

Locations (3)

Moscow Clinical Scientific Center named after AS Loginov

Moscow, Not Required, Russia

RECRUITING

FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia

Moscow, Not Required, Russia

RECRUITING

FSBI "National medical research center for obstetrics, gynecology and perinatology named after academician VI Kulakov" Ministry of healthcare of the Russian Federation

Moscow, Russia

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Relative dose-intensity (RDI) of the myelosupressive therapy course

Time frame: 12 months

Secondary Outcomes

RDI of 6 x TC, 6 x TCHP, ddAC x4 -> 4 x paclitaxel , dd4AC -> 4 x paclitaxel + 12 x carboplatin) regimens performed in relation to (neo) adjuvant therapy of breast cancer

Time frame: 18 months

RDI of FOLFOX-, FOLFOXIRI-based regimens performed in relation to (neo) adjuvant therapy of colorectal cancer

Time frame: 18 months

RDI of FOLFOX-, FOLFOXIRI-based regimens performed in relation to patients with potentially resectable liver metastases of colorectal cancer

Time frame: 18 months

RDI of DCF-, FOLFORINOX-based regimens performed in relation to therapy of pancreatic cancer

Time frame: 18 months

RDI of DCF-, FOLFORINOX-, FLOT-, FOLFOX-based regimens performed in relation to therapy of gastric and esophageal cancers

Time frame: 18 months

RDI of chemotherapy courses performed in patients with cervical cancer and sarcoma of the uterus after irradiation of the pelvic organs

Time frame: 18 months

The complete pathological responses (pCR) rate in the primary tumors for patients diagnosed with HER2 + and triple negative early breast cancer requiring neoadjuvant treatment

Time frame: 18 months

The complete pathological responses (pCR) rate in the malignant lymph nodes for patients diagnosed with HER2 + and triple negative early breast cancer requiring neoadjuvant treatment

Time frame: 18 months

The incidence of febrile neutropenia with empegfilgrastim supportive therapy compared with historical control

Time frame: 18 months

The incidence of neutropenia leading to a dose reduction of cytostatic drugs and / or an increase of the interval between cycles when using empegfilgrastim supportive therapy compared with historical controls

Time frame: 18 months

Completed cases number of (neo) adjuvant therapy

Time frame: 18 months

The incidence of severe infections (grade 3-4)

Time frame: 18 months

Frequency of antibiotic prescription

Time frame: 18 months

Frequency of study withdrawal due to adverse events

Time frame: 18 months

RCB rate in patients with breast cancer

Time frame: 18 months

Any grade adverse events frequency

Time frame: 18 months

Serious adverse events frequency

Time frame: 18 months

Central Contacts

Lyudmila Zhukova, MD, PhD, professor

CONTACT

+74953043035 lyudmila.zhukova@mail.ru

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.